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OBJECTIVE—The vascular ectonucleotidase ENTPD1 protects
against renal injury and modulates glucose homeostasis in mouse
models. We sought to determine whether human variation in
ENTPD1 inﬂuences predisposition to diabetes or diabetic
nephropathy.
RESEARCH DESIGN AND METHODS—We analyzed ENTPD1
single nucleotide polymorphisms (SNPs) in 363 African American
control subjects, 380 subjects with type 2 diabetes and end-stage
renal disease (DM-ESRD), and 326 subjects with ESRD unrelated to
diabetes (non–DM-ESRD). Using human cell lines, we correlated
disease-associated ENTPD1 haplotypes with ENTPD1 gene expres-
sion. Finally, we studied consequences of ENTPD1 deletion in a
mouse model of type 2 diabetes (db/db).
RESULTS—A common ENTPD1 two-SNP haplotype was asso-
ciated with increased risk for DM-ESRD (P  0.0027), and an
uncommon four-SNP haplotype was associated with protection
against DM-ESRD (P  0.004). These haplotypes correlated with
ENTPD1 gene expression levels in human cell lines in vitro.
Subjects with high ENTPD1-expressing haplotypes were en-
riched in the DM-ESRD group. By crossing ENTPD1-null mice
with db mice, we show that ENTPD1 deletion has prominent
effects on metabolic syndrome traits. Speciﬁcally, deletion of
ENTPD1 lowered glucose levels in control (db/) mice with
one functional leptin receptor and dramatically lowered
weights in db/db mice with no functional leptin receptors.
Similar effects were seen in aged ENTPD1-null mice with
normal leptin receptors.
CONCLUSIONS—ENTPD1 polymorphisms appear to inﬂuence
susceptibility to type 2 diabetes and/or diabetic nephropathy in
African Americans. Studies in human cell lines and in vivo mouse
data support a potential role for ENTPD1 genetic variation in
susceptibility to type 2 diabetes. Diabetes 58:999–1006, 2009
D
iabetes and its complications are enormous
sources of mortality, morbidity, and cost in the
U.S. African Americans are especially prone to
diabetes and diabetic kidney disease (1). Ge-
netic variation plays a major role in susceptibility to both
development of diabetes and onset of diabetic renal injury
(2,3). Finding genes responsible for this predisposition to
disease could help predict who may be at high risk and
also identify important pathways involved in disease
pathogenesis.
ENTPD1, also known as CD39, is an ectonucleotidase
that hydrolyzes ATP and ADP to AMP, initiating an enzy-
matic cascade that leads to the generation of adenosine
(4). By regulating nucleotide levels, ENTPD1 controls the
activity of both purinergic receptors (P2X and P2Y) and
downstream adenosine (P1) receptors. ENTPD1 is widely
expressed, particularly in blood vessels and on cells of the
immune system (5–7). ENTPD1 is present in glomeruli,
afferent arterioles, and larger vessels of the kidney (8,9).
Mice null for ENTPD1 sustained markedly more severe
renal injury than wild-type mice in models of type 1
diabetes (9) and ischemia reperfusion injury (10).
Previously, a locus for susceptibility to diabetic and
nondiabetic renal disease was located on human chromo-
some 10q24 in African Americans (11). Subsequently,
others have also found loci in this chromosomal region
associated with renal dysfunction in Caucasians with type
2 diabetes (12). It appears likely that one or more genes
with effects on nephropathy are located in this region.
ENTPD1 is located close to the linkage peak in both of
these studies. More recently, we have reported that EN-
TPD1-null mice also exhibit abnormalities of glucose
homeostasis (13). The close functional relationship be-
tween ENTPD1 and another ectonucleotidase that inﬂu-
ences metabolic syndrome traits in humans, ENPP1, (14)
suggests that ENTPD1 could affect glucose homeostasis in
humans as well.
To determine whether variation in ENTPD1 might inﬂu-
ence the development of diabetes or diabetic renal dis-
ease, we tested the frequency of single nucleotide
polymorphisms (SNPs) in ENTPD1 in three groups of
African American patients: 363 healthy control subjects,
326 patients with nondiabetic end-stage renal disease
(non–DM-ESRD), and 380 patients with ESRD caused by
type 2 diabetes (DM-ESRD). We support these genetic
association results with functional studies in vitro using
human cell lines and in vivo using mouse models with
nonfunctional leptin receptors (db/db). We show that
ENTPD1 gene expression in human cell lines correlates
with the disease-associated genotypes, and mice null for
ENTPD1 share metabolic phenotypes with humans who
have low ENTPD1-expressing genotypes.
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Collection of control and case subjects has been described previously (15,16).
Brieﬂy, all subjects were recruited in North Carolina, South Carolina, Georgia,
Virginia, or Tennessee, and all were born in one of these ﬁve southeastern
states. A total of 363 unrelated African American control subjects were
recruited through community screening events, all without a history of type 2
diabetes or renal disease. A total of 380 unrelated African American patients
with type 2 diabetes and ESRD were recruited (DM-ESRD group) from dialysis
clinics. A total of 326 unrelated African American patients with ESRD but
without a history of diabetes (non–DM-ESRD) were also recruited from
dialysis clinics. A single investigator (B.I.F.) classiﬁed all ESRD patients into
DM-ESRD or non–DM-ESRD groups. Non–DM-ESRD patients included those
with hypertension-associated ESRD or primary glomerular diseases. The
DM-ESRD groups included patients with either 1) diabetes and histologic
evidence of diabetic nephropathy or 2) with diabetes 5 years before the
initiation of renal replacement therapy and either diabetic retinopathy or
proteinuria 500 mg per 24 h. DM-ESRD patients had no other known cause
of renal disease. Patients with renal cystic diseases, hereditary nephritis, or
ESRD related to urologic disease were all excluded from analysis.
Genotyping. A total of 18 SNPs tagging 80% of the known SNPs in the Yoruba
(YRI) Hapmap population were selected using the program Tagger (www.
broad.mit.edu/mpg/tagger). Tag SNPs all had minor allele frequency of 5%.
rs3793744, the only common nonsynonymous coding variant in ENTPD1, was
force inserted in SNP selection. Tag SNPs spanned the ENTPD1 gene on
chromosome 10 from 97.504 to 97.613 Mb. We used a Sequenom MassArray
platform (17) for genotyping.
Genetic analysis. SNPs with call rates 96% were excluded from analysis.
All SNPs were in conformation with Hardy-Weinburg equilibrium (P  0.05) in
control subjects. Determination of haploblock structures and associations
were performed using Haploview (www.broad.mit.edu/mpg/haploview). Hap-
lotypes with frequency 1% were included in the analysis. Permutation testing
for haplotype associations was performed using Haploview software at 10,000
permutations.
In vitro ENTPD1 expression studies. Genotyped, Epstein-Barr virus–
transformed lymphoblasts from the YRI HapMap (www.hapmap.org) collec-
tion and Perlegen (www.perlegen.com) African American panel were used for
analysis. Cells were grown in RPMI-1640 media with 2 mmol/l L-glutamine, 15%
fetal bovine serum, penicillin-streptomycin mix, and 10 mmol/l Hepes buffer.
Cells were seeded at 200,000 per ml and harvested 24–48 h later in log-phase
growth. Then, mRNA was isolated using RNeasy (Qiagen) according to the
manufacturer’s instructions. A total of 0.5 g of mRNA was reversed tran-
scribed to cDNA using the Taqman Reverse Transcription Kit (Applied
Biosystems). Probe-primer sets for ENTPD1 and the 18S ribosomal subunit
(loading control) were obtained from Applied Biosystems. Real-time PCR was
performed on an Applied Biosystems 7700 system. ENTPD1 mRNA expression
was normalized using 18S expression.
For protein isolation, cells were washed twice with ice-cold PBS and then
lysed in an NP-40–based buffer with protease inhibitors (Roche mini-tabs). A
total of 40 g of protein were separated on a gradient gel under nonreducing
condtions and transferred to polyvinylidene ﬂuoride paper (Millipore) using a
semidry transfer apparatus. For ENTPD1, we used a mouse monoclonal
antibody (BU-61; Ancell) and a goat anti-mouse secondary antibody (Pierce).
We used anti–glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody
(Ambion) as a loading control. Band density was quantiﬁed with a Kodak
ImageStation 2000M, and protein level was expressed as a ratio of ENTPD1 to
GAPDH.
In silico, expanded ENTPD1 expression studies. For YRI HapMap sub-
jects, ENTPD1 gene expression levels were downloaded from (http://www.
sanger.ac.uk/humgen/genevar/). Methods for the generation of this data are
described by Stranger et al. (18). Genotypes were obtained from www.
hapmap.org. Statistics were performed using Student’s t test on log
2-trans-
formed data.
Enzyme activity. A total of 250,000 lymphocytes were harvested in log-phase
growth. ATPase and ADPase activity were determined with a Malachite Green
assay for phosphate production as described previously using 200 mol/l
nucleotide as the substrate during a 10-min incubation (19). Tetramisole was
used to inhibit alkaline phosphatases (19).
Animal studies. All mouse studies were done with institutional animal care
and use committee approval at Beth Israel Deaconess Medical Center. Mice in
all four db groups originated from crossing db/ heterozygote breeders on a
C57/BL6 background from Jackson Labs with ENTPD1
/ breeders back-
crossed more than six times on a C57/BL6 background. Diabetic mice were
db/db offspring with or without ENTPD1, and db/ offspring were used as
controls. In the aging study, male ENTPD1
/ mice backcrossed more than
six times onto a C57/BL6 background were compared with age- and strain-
matched C57/BL6 wild-type controls.
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ENTPD1, AFRICAN AMERICANS, AND ESRD
1000 DIABETES, VOL. 58, APRIL 2009Animal phenotyping. Albuminuria was quantiﬁed using an albumin-to-
creatinine ratio. Albumin was measured using the Albuwell-M Kit from
Exocell, and creatinine was measured using the Creatinine Companion from
Exocell. Blood glucose was measured using a One Touch Ultra 2 glucometer
(Lifescan). For the db-based studies, nonfasting glucose levels were measured
at 3:00 P.M. For the non-db studies (aging), glucose levels were measured after
an 8-h daytime fast.
For histopathology, mouse kidney tissue was ﬁxed in 10% buffered formalin
and embedded in parafﬁn then cut into 3-micron sections and stained with
PAS stain. Glomerular area was calculated using Spot Imaging software. The
glomerular sclerosis index has been described previously (9).
RESULTS
Using a set of markers chosen with the program Tagger,
we genotyped 18 SNPs (minor allele frequency 5%) in
ENTPD1 that were predicted to cover 80% of the known
SNPs in the Yoruba (YRI) Hapmap population. Seventeen
of 18 SNPs passed quality standards and conformed to
Hardy-Weinburg equilibrium criteria as described in RE-
SEARCH DESIGN AND METHODS above. These 17 SNPs tagged
79% of YRI HapMap SNPs.
Location of SNPs in the ENTPD1 gene, minor allele
frequency of each SNP, and uncorrected P values in the
populations in this study are shown in Table 1. When
control subjects and subjects with non–DM-ESRD were
compared, one SNP (rs6584026) showed nominal signiﬁ-
cance (P  0.027). Comparing control subjects and sub-
jects with DM-ESRD revealed two SNPS (rs12763743 and
rs3897983) that were nominally signiﬁcant (0.041 and
0.037, respectively).
We considered the possibility that the two nominally
signiﬁcant SNPs for DM-ESRD might have additive effects.
We used the two signiﬁcant SNPs discovered in the
DM-ESRD population to form a two-SNP haplotype for
further analysis. Three common combinations accounted
for all subjects tested (AG  82.9%, AA  10.8%, and TG 
6.3%). The most common haplotype (AG) appeared to
confer increased risk of diabetes and/or diabetic nephrop-
athy (P  0.0027, P  0.009 after permutation; odds ratio
1.51) compared with the other two haplotypes, which were
both nominally associated with protection from diabetes
and/or diabetic nephropathy (Table 2). We refer to the AG
haplotype as the two-SNP risk haplotype, and the com-
bined group of AA and TG haplotypes as the two-SNP
protective haplotypes. No difference was seen with re-
spect to these two-SNP risk or protective haplotypes when
comparing control subjects with non–DM-ESRD subjects.
A broader, unbiased haplotype analysis using all suc-
cessfully genotyped SNPs showed that 16 of the SNPs fell
into a single haplotype block deﬁning 10 haplotypes with
frequency 1%. One haplotype was associated with pro-
tection against diabetes and/or diabetic nephropathy with
P  0.004 (odds ratio 0.34). This statistical signiﬁcance of
this protective haplotype remained unchanged when re-
duced to four SNPs (rs4918972, rs10748648, rs1342790,
and rs3793744; GAGA in Table 2). After permutation
analysis, the P value remained signiﬁcant at 0.017. The
GAGA haplotype is referred to as the four-SNP protective
haplotype. This protective haplotype included the uncom-
mon variant rs3793744, a coding SNP in exon 7 causing a
valine to isoleucine substitution. No association was seen
for this haplotype when comparing control subjects to
non–DM-ESRD subjects.
We made several additional comparisons to help deﬁne
whether our haplotypes were associated with diabetes or dia-
betic nephropathy. First, we compared healthy control subjects
with all ESRD subjects (both DM-ESRD and non–DM-ESRD)
and found much weaker associations for both the two-SNP and
four-SNP haplotypes (supplementary Table 1 [available in an
online appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db08-1214/DC1]). Then we compared non–DM-
ESRD with DM-ESRD subjects: the two-SNP (AG) risk
haplotype remained robust (P  0.0038, odds ratio 1.53), while
the four-SNP (GAGA) protective haplotype lost some statistical
power (P0.024), though the odds ratio was unchanged (odds
ratio 0.37) when non-ESRD subjects were substituted for
control subjects. We also pooled healthy control subjects and
non–DM-ESRD subjects into a nondiabetic group and
compared them with DM-ESRD subjects. Here, the P value of
the two-SNP (AG) risk haplotype improved to 0.0008 (odds ratio
1.51), while the four-SNP (GAGA) protective haplotype was
similar to the control versus DM-ESRD comparison (P0.0056,
odds ratio 0.37). Taken together, these analyses tend to support
a genetic association with diabetes rather than diabetic
nephropathy.
To determine whether either of these disease-associated
haplotypes correlated with general expression levels of
ENTPD1, we took advantage of the fact that ENTPD1 is
highly expressed on B-lymphocytes (6). For the two-SNP
haplotype, we examined YRI Hapmap lymphoblasts for
subjects who were homozygous for the three different
haplotype groups. While many subjects in the YRI popula-
tion were homozygous for the AG risk haplotype, only two
TABLE 2
Haplotypes
Haplotype Frequency Control subjects Case subjects 
2 P Odds ratio (95% CI)
Two-SNP haplotypes
AG 0.829 0.799 0.857 9.0 0.0027 1.51 (1.15–1.99)
AA 0.108 0.124 0.091 4.2 0.0404 0.70 (0.51–0.98)
TG 0.063 0.077 0.051 4.1 0.0431 0.64 (0.42–0.98)
Four-SNP haplotypes
GAGG 0.432 0.428 0.436 0.10 0.7495 1.03 (0.84–1.27)
GTAG 0.393 0.386 0.398 0.23 0.6323 1.05 (0.85–1.30)
ATAG 0.139 0.141 0.138 0.04 0.8336 0.97 (0.72–1.30)
GAGA 0.023 0.035 0.012 8.26 0.0041 0.34 (0.16–0.73)
GTGA 0.013 0.010 0.016 0.09 0.3259 1.67 (0.65–4.26)
Association of DM-ESRD with two-SNP haplotypes consisting of the two nominally signiﬁcant SNPs rs12763743 and rs3897983. The AG
haplotype is referred to as the two-SNP risk haplotype, and the AA and TG haplotypes are referred to as the two-SNP protective haplotypes.
Association of DM-ESRD with four-SNP haplotypes consisting of rs4918972, rs10748648, rs1342790, and rs3793744. The GAGA haplotype is
referred to as the four-SNP protective haplotype.
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only one was homozygous for the TG protective haplo-
type. Since the AA and TG haplotypes were almost iden-
tical in terms of risk (P  0.04, nominally protective) and
odds ratios (0.70 and 0.64, respectively), we pooled these
into a single group and compared ENTPD1 expression
from their lymphocytes with those from the risk (AG)
haplotype group using real-time PCR (Fig. 1A). Lympho-
cytes homozygous for the AG risk haplotype had 39%
higher ENTPD1 expression levels than homozyogotes for
the protective AA or TG haplotypes (protective 5.62  0.36
vs. risk 7.81  0.36; P  0.007), with no overlap between
groups (range 5.09–6.30 for protective and 6.91–9.53 for
risk). Not enough cell lines homozygous for the four-SNP
protective haplotype (one cell line) were available for
comparison.
To provide additonal support for a correlation between
haplotype and expression level, we used gene expression
data from Stranger et al. (18) generated from YRI HapMap
cell lines, which allowed us to incorporate haplotype
heterozygotes into the analysis. For consistency, we ana-
lyze the two- and four-SNP haplotypes in terms of number
of protective alleles. We pooled subjects with one or two
protective alleles for the two-SNP haplotype and com-
pared them with subjects with no protective alleles (two
risk alleles). Subjects with zero protective haplotypes (n 
31) expressed 16% more ENTPD1 than subjects with one
or two protective haplotypes (n  29; P  0.027) (Fig. 1B).
We then pooled subjects with one or two copies of the
protective four-SNP allele (n  7) and compared them
with those with no copies (n  53). While the difference
was not signiﬁcant (P  0.09), those with no protective
alleles expressed 16% more ENTPD1 than those with one
or two protective alleles (Fig. 1C). These cell lines with at
least one protective four-SNP allele had the lowest mRNA
expression levels of any haplotype group, including the
protective two-SNP haplotype. To account for the fact that
we were comparing subjects with protective four-SNP
alleles versus a pool that contained many more subjects
with one or more protective two-SNP allele, we then
compared subjects based on their total number of protec-
tive alleles (two-SNP protective alleles plus four-SNP
protective alleles) to integrate the effects of two-SNP and
four-SNP haplotypes on ENTPD1 expression. Those with
no protective alleles (n  29) expressed 18% more
ENTPD1 than subjects with at least one protective two-
SNP allele or one protective four-SNP allele (n  31) (P 
0.01). Both haplotypes appear to correlate with ENTPD1
expression and were especially predictive of mRNA ex-
pression levels when used in tandem. The small number of
subjects with the protective four-SNP allele prevented us
from determining whether the effects of the two-SNP and
four-SNP haplotypes were independent.
The protective four-SNP haplotype (GAGA) included a
SNP causing an amino acid change (rs3793744: V to I at
position 293). A second, uncommon haplotype (GTGA)
also included the minor allele (A) at rs3793744 but was not
associated with DM-ESRD when compared with control
subjects. We compared expression levels between cell
lines with one or more copies of each of these haplotypes.
Remarkably, the nonprotective (GTGA) four-SNP haplo-
type including the minor allele at rs3793744 expressed 45%
more ENTPD1 mRNA than the protective (GAGA) four-
SNP allele with the same SNP at rs3793744 (n  3 vs. n 
7, P  0.0006). This ﬁnding suggests that differences in
mRNA expression underly the effect of the four-SNP
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FIG. 1. A: ENTPD1 mRNA expression by real-time PCR comparing YRI
Hapmap cell lines homozygous for the two-SNP risk haplotype AG (n 
7) versus the protective haplotypes AA and TG (n  3), normalized for
18S expression. ENTPD1 mRNA levels are 39% higher in cell lines with
zero protective haplotypes than in cell lines with two protective
haplotypes. B: In silico ENTPD1 expression for YRI cell lines with zero
(n  31) versus one or two (n  29) copies of the two-SNP protective
haplotypes AA and TG. Zero copies of the protective haplotype con-
ferred 16% higher levels of ENTPD1 expression. C: ENTPD1 expres-
sion for YRI cell lines with zero (n  53) versus one or two (n  7)
copies of the four-SNP protective (GAGA) haplotype. Zero copies of
the protective haplotype were associated with 16% higher ENTPD1
expression. Though nonsigniﬁcant, cell lines with one or two protec-
tive copies had lower expression than all other groups tested. D:
Protective index incorporating both the two- and four-SNP haplotypes.
The total number of protective two- and four-SNP protective alleles
was summed for each cell line. Cell lines with zero protective alleles
(n  29) had 18% more ENTPD1 expression than cell lines with at least
one protective allele (n  31). E: Comparison of ENTPD1 mRNA
expression of protective four-SNP haplotype (GAGA, n  7) and
uncommon four-SNP haplotype (GTGA, n  3) that share the minor
allele (A) at rs3793744 that codes for a valine to isoleucine substitu-
tion at amino acid 293. The difference indicates that rs3793744 is not
itself the causal SNP.
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note, though, that protein expression in the homozygotes
for the protective four-SNP haplotype were surprisingly
low compared with other cell lines (supplementary Fig. 1A
and B). This ﬁnding was demonstrated in single samples
from two separate collections (HapMap and Perlegen),
and activity assays showed that the effect was not due to
differential antibody binding at the amino acid change at
position 293 (rs3793744) (supplementary Fig. 1C and D).
To further investigate the effects of ENTPD1 on either
diabetes or diabetic nephropathy, we crossed ENTPD1-
null mice with db/db mice to create a type 2 model of
diabetes and type 2 diabetic nephropathy. Assessment for
renal injury at 8 months of age demonstrated that in the
nondiabetic mice (db/), ENTPD1 deletion caused mildly
increased albuminuria (wild type  37.2  2.3 g/mg vs.
knockout  54.7  6.7 g/mg; P  0.028) and a trend
toward increased glomerular sclerosis (Fig. 2A and B). In
the diabetic groups, there were no differences in albumin-
uria, sclerosis index, or glomerular area between db/db
mice with and without ENTPD1 (Fig. 2C–E).
Metabolic syndrome parameters revealed more dramatic
differences. In nondiabetic mice, nonfasting (3:00 P.M.) glu-
cose was lower in ENTPD1-null mice at both 8 weeks (wild
type  208.1  4.8 mg/dl vs. knockout  176.8  7.8 mg/dl;
P  0.006) and 6 months (wild type  179.2  5.7 mg/dl vs.
knockout  161.9  5.8 mg/dl; P  0.039) (Fig. 3A and B). No
differences in glucose levels were seen in the db/db groups at
these time points with or without ENTPD1 (Fig. 3C and D).
While weights of nondiabetic mice were no different (Fig. 4A
and B), large differences were seen in db/db mice, with
deletion of ENTPD1 protecting against obesity in the db/db
mice at both 8 weeks (wild type  41.4  1.0 g vs. knock-
out  37.6  1.4 g; P  0.026) and 6 months (wild type 
62.4  0.9 g vs. knockout  52.0  1.3 g; P  0.000001) (Fig.
4C and D).
We also aged wild-type and ENTPD1-null mice (leptin
receptor normal) to see if aging would cause similar
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FIG. 2. A: Albumin-to-creatinine ratio for db/ nondiabetic mice. n  7 for ENTPD1 wild type and n  12 for ENTPD1 knockout. B: Sclerosis index
for db/ nondiabetic mice. n  7 for ENTPD1 wild type and n  12 for ENTPD1 knockout. C: Albumin-to-creatinine ratio for db/db mice. n  13
for ENTPD1 wild type and n  9 for ENTPD1 knockout. D: Sclerosis index for db/db mice. n  13 for ENTPD1 wild type and n  10 for ENTPD1
knockout. E: Glomerular area for db/db mice. n  10 for ENTPD1 wild type and n  8 for ENTPD1 knockout.
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years of age, ENTPD1-null mice had markedly lower
fasting glucoses (wild type  141.6  5.1 mg/dl vs.
knockout  112.8  3.3 mg/dl; P  0.0009) and lower
weights (wild type  46.4  2.7 g vs. knockout  39.2 
0.7; P  0.042) than wild type controls (Fig. 5A and B).
Consistent with the db experiments, we did also note
increased albuminuria in aged ENTPD1-null mice despite
lower weights and blood glucoses (D.J.F., unpublished
data).
DISCUSSION
Our previous studies in ENTPD1-null mice suggested a
role for this ectonucleotidase in both resistance to renal
injury and in glucose homeostasis. We tested polymorphic
markers in the ENTPD1 gene in humans for association
with diabetic ESRD and nondiabetic ESRD in African
Americans, a group of Americans with high rates of both
diseases. We found two common polymorphisms
(rs12763743 and rs3897983) that are nominally associated
with diabetic but not nondiabetic ESRD. When used
together, these two polymorphisms showed even stronger
association (P  0.0027) with subjects in the diabetic
nephropathy group. These two SNPs may represent inde-
pendent, additive effects or they may together tag a causal
SNP better than either of the SNPs alone. More general
haplotype analysis also identiﬁed an uncommon four-SNP
haplotype that appears to protect against diabetes or
diabetic nephropathy (P  0.004). The effect size of this
uncommon haplotype is strong, conferring a relative risk
of 0.34. Additional groupwise comparisons using pooled
groups further suggested that the association was due to
diabetes rather than nephropathy in the DM-ESRD groups.
To support association the association of ENTPD1 with
diabetes and/or diabetic nephropathy, we tested HapMap
cell lines derived from African subjects for ENTPD1
expression. Cell lines homozygous for the two-SNP (AG)
risk haplotype expressed 39% more ENTPD1 mRNA than
those cell lines with two protective haplotypes (AA and
TG). We performed additional bioinformatic analysis that
showed similar results: zero alleles of the two-SNP protec-
tive haplotypes led to 16% greater ENTPD1 expression
than one or two protective alleles. The protective four-
SNP haplotype also showed a trend toward lower ENTPD1
expression levels, though this analysis was limited by
fewer representative cell lines and was confounded by
comparison with a group including many protective two-
SNP haplotypes. In fact, the protective four-SNP haplotype
showed the lowest ENTPD1 expression of any group. By
using an index that took into account the total number of
both the two- and four-SNP protective haplotypes, we
identiﬁed a strong correlation between genotype and
ENTPD1 mRNA expression level using both haplotypes
derived from our genetic association study. Additional
experiments measuring ENTPD1 protein levels conﬁrmed
that the protective four-SNP haplotype was associated
with very low ENTPD1 levels and may suggest an effect
beyond mRNA expression, though we did not have sufﬁ-
FIG. 3. A and B: Blood glucose levels for db/ nondiabetic mice at 8 weeks (A) and 6 months (B). n  9 for ENTPD1 wild type and n  12 for
ENTPD1 knockout. C and D: Blood glucose levels for db/db mice at 8 weeks (C) and 6 months (D). n  19–20 for ENTPD1 wild type and n  12–13
for ENTPD1 knockout.
ENTPD1, AFRICAN AMERICANS, AND ESRD
1004 DIABETES, VOL. 58, APRIL 2009cient samples available to us to prove this hypothesis
deﬁnitively.
We also used genetic studies in mice to assess the role
of ENTPD1 on diabetes and diabetic nephropathy. While
ENTPD1-null control mice did have increased albuminuria
compared with wild-type mice, perhaps the more striking
ﬁndings related to metabolic syndrome traits. In particu-
lar, ENTPD1-null mice had lower glucose levels in the
absence of the homozygous db/db mutation and dramati-
cally lower weights in the presence of the db/db mutation.
Notably, previous work demonstrated that ENTPD1-null
mice have higher leptin levels than wild-type mice (13),
potentially a compensatory response that is disabled in the
absence of one or both copies of the normal leptin
receptor. The exact reason for this differential effect in
db/db and db/ mice on blood glucose and weight still
remains to be elucidated. However, even in the presence
of normal leptin signaling, using wild-type mice rather
than db/ heterozygotes as controls, aging accentuated
both phenotypes (i.e., difference in glucose homeostasis
and weight gain). Our mouse ﬁndings again suggest that
the effect we discovered in humans may relate to low
ENTPD1 protecting against diabetes in control subjects,
though increased albuminuria in the nondiabetic CD39-
null mice may point toward an effect on renal disease as
well.
Further support for association between ENTPD1 and
diabetes and diabetic nephropathy is the ﬁnding that
FIG. 4. A and B: Weights for db/ nondiabetic mice at 8 weeks (A) and 6 months (B). n  9 for ENTPD1 wild type and n  12 for ENTPD1
knockout. C and D: Weights for db/db mice at 8 weeks (C) and 6 months (D). n  19–20 for ENTPD1 wild type and n  13–15 for ENTPD1
knockout.
FIG. 5. A: Fasting glucose levels in mg/dl for 2-year-old wild-type (n  8) and ENTPD1-null (n  6) mice. B: Weight at 2 years in wild-type (n 
7) and ENTPD1-null (n  11) mice.
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markably similar enzymatic mechanism, ENPP1, have also
been associated with both diabetes and diabetic nephrop-
athy. Nephropathy has been associated with ENPP1 poly-
morphisms, ﬁrst in Caucasian populations (20–22), and
subsequently in an African American population that in-
cluded our subjects (23). Polymorphisms in the same gene
also have an important inﬂuence on metabolic syndrome
traits (14), and there appears to be an important interac-
tion between weight and glucose homeostasis (24,25), just
as we see with ENTPD1 in mice. While ENPP1 hydrolyzes
extracellular ATP to AMP and pyrophosphate, ENTPD1
hydrolyzes extracellular ATP to AMP and two phosphate
molecules. Low functional expression of either of these
ectoenzymes could increase extracellular levels of ATP
and decrease levels of the nucleoside adenosine.
The strength of our study rests on mutually supportive
data built from genetic association of human disease with
genetic variants, gene expression levels that correlate with
the disease-associated haplotypes, and a mouse model
that shows phenotypic differences based on expression
level of the gene. Ultimately, replication in larger cohorts
will be needed to validate our ﬁndings. Our data, along
with previous studies with ENPP1, suggest that extracel-
lular nucleotide metabolism may be a critical determinant
of diabetes and/or diabetic nephropathy.
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